Mike Teiler – Innovating Type 1 Diabetes Treatment

The Big Experiment

My son was diagnosed with type 1 diabetes at the age of 13.
Which is why this episode is very close to my heart. There are big life-altering challenges for the patient and their family in managing type 1 diabetes. With limitations to the current insulin therapies that make the work of my guest in the episode, Mike Teiler, all the more important.
Mike is the Chief Pharmaceutical Officer at LeviCure, a startup focused on new approaches to type 1 diabetes. In this episode we discuss the difference between type 1 and type 2 diabetes. And explore the development of LeviCure's triple therapy, which combines three existing drugs to improve glycaemic control and potentially achieve remission in type 1 diabetes patients.
A therapy that has shown promising results in both recent onset and established patients. We discuss the potential of repurposing existing drugs for the treatment of type 1 diabetes. As well as the funding required and the clinical trial process that will be undertaken to be able to launch the therapy.
“Many of them completely stopped insulin injections.” – Mike Teiler
You’ll hear about:
01:10 - The difference between type & type 2 diabetes

04:03 - The lifechanging nature of type 1 diabetes

06:40 - The LeviCure story

11:16 - The effect of weening people off of insulin

15:08 - Oral drugs that could replace insulin

18:48 - Disentangling the honeymoon effect

20:15 - The effects on established patients

25:02 - The pharmaceutical benefits of this therapy

27:58 - The intellectual property perspective

30:43 - The democratic nature of these new therapies

34:15 - What are the clinical phases?

41:08 - Making sure the therapies hit the target

43:44 - The fundraising needed

Follow Mike:

LinkedIn - https://www.linkedin.com/in/miketeiler/

LeviCure on LinkedIn - https://www.linkedin.com/company/levicure-ltd/

LeviCure - https://www.levicure.com/

Connect with me:

LinkedIn: https://www.linkedin.com/in/markdavison100/

Grant Instruments: https://www.grantinstruments.com/

Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/

Chapters

1. Mike Teiler – Innovating Type 1 Diabetes Treatment (00:00:00)

2. The difference between type & type 2 diabetes (00:01:10)

3. The lifechanging nature of type 1 diabetes (00:04:03)

4. The LeviCure story (00:06:40)

5. The effect of weening people off of insulin (00:11:16)

6. Oral drugs that could replace insulin (00:15:08)

7. Disentangling the honeymoon effect (00:18:48)

8. The effects on established patients (00:20:15)

9. The pharmaceutical benefits of this therapy (00:25:02)

10. The intellectual property perspective (00:27:58)

11. The democratic nature of these new therapies (00:30:43)

12. What are the clinical phases? (00:34:15)

13. Making sure the therapies hit the target (00:41:08)

14. The fundraising needed (00:43:44)